Who are Radiotherapy and PCV chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Concurrent chemo-radiotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/radiotherapy-and-pcv-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Radiotherapy and PCV chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiotherapy and PCV chemotherapy (Radiotherapy and PCV chemotherapy) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy and radiation therapy. Area: Oncology.

phase 3 Combination chemotherapy and radiation therapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Radiotherapy and PCV chemotherapy (Radiotherapy and PCV chemotherapy) — Hospices Civils de Lyon. This combination uses ionizing radiation to destroy tumor cells directly while chemotherapy with procarbazine, lomustine, and vincristine (PCV) enhances cell death through DNA damage and mitotic inhibition.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Radiotherapy and PCV chemotherapy TARGET	Radiotherapy and PCV chemotherapy	Hospices Civils de Lyon	phase 3	Combination chemotherapy and radiation therapy
Concurrent chemo-radiotherapy	Concurrent chemo-radiotherapy	Sun Yat-sen University	phase 3	Combination chemotherapy and radiation therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy and radiation therapy class)

Hospices Civils de Lyon · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Radiotherapy and PCV chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/radiotherapy-and-pcv-chemotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab